5-Azacytidine was first synthesized almost 40 years ago. It was demonstrated to have a wide range of antimetabolic activities when tested against cultured cancer cells and to be an effective chemotherapeutic agent for acute myelogenous leukemia. However, because of 5-azacytidine's general toxicity, other nucleoside analogs were favored as therapeutics. The finding that 5-azacytidine was incorporated into DNA and that, when present in DNA, it inhibited DNA methylation, led to widespread use of 5-azacytidine and 5-aza-2'-deoxycytidine (Decitabine) to demonstrate the correlation between loss of methylation in specific gene regions and activation of the associated genes. There is now a revived interest in the use of Decitabine as a therapeutic agent for cancers in which epigenetic silencing of critical regulatory genes has occurred. Here, the current status of our understanding of the mechanism(s) by which 5-azacytosine residues in DNA inhibit DNA methylation is reviewed with an emphasis on the interactions of these residues with bacterial and mammalian DNA (cytosine-C5) methyltransferases. The implications of these mechanistic studies for development of less toxic inhibitors of DNA methylation are discussed.
Introduction 5-azacytidine and 5-aza-2'-deoxycytidine (ZCyd and ZdCyd -See Figure 1 for structures) were first synthesized by Piskala and Sorm (1964) . ZCyd was originally developed and tested as a nucleoside antimetabolite with clinical specificity for acute myelogenous leukemia (Cihak, 1974; Sorm et al., 1964) . Early reports indicated that ZCyd was an inducer of chromosome breakage and a mutagen (Halle, 1968; Karon and Benedict, 1972; Landolph and Jones, 1982; Paul, 1982; Viegas-Pequignot and Dutrillaux, 1976) . Because it could be activated to the nucleoside triphosphate and incorporated into both DNA and RNA, ZCyd treatment of cells led to inhibition of DNA, RNA and protein synthesis (reviewed in Vesely and Cihak, 1978) . Incorporation of ZCyd into tRNA was shown to inhibit tRNA methyltransferases (Lu and Randerath, 1980) , and to interfere with tRNA methylation and processing leading to defective acceptor function of transfer RNA (Lee and Karon, 1976) . Since methylation also plays an important role in ribosomal RNA processing (Glazer et al., 1980; Weiss and Pitot, 1974) , effects of incorporation of ZCyd on RNA function and stability are likely to account for much of ZCyd's effect on protein synthesis. In addition, enzymatic deamination of ZCyd and ZdCyd yields 5-azauridine and 5-aza-2'-deoxyuridine respectively. These compounds interfere with de novo thymidylate synthesis, adding to cytotoxicity (Vesely et al., 1969) .
5-Aza-2'-deoxycytidine (ZdCyd), which is only incorporated into DNA (Li et al., 1970) , is at least 10-fold more cytotoxic than ZCyd for cultured cells and animals (Flatau et al., 1984; Momparler et al., 1984) . At dose levels low enough to avoid triggering cell death, incorporation of ZCyd or ZdCyd into DNA of cultured cells leads to rapid loss of DNA (cytosine-C5) methyltransferase (DNA (C5) MTase, Dnmt) activity because the enzyme becomes irreversibly bound to ZCyt residues in DNA (Christman et al., 1983; Creusot et al., 1982; Taylor and Jones, 1982) . Studies in bacteria, cultured cells and rodents indicate that these Dnmt-ZCyt adducts are toxic and mutagenic if not repaired (Bhagwat and Roberts, 1987; Jackson-Grusby et al., 1997; Juttermann et al., 1994) . However, DNA (C5) MTases only bind to ZCyt or other inhibitory Cyt analogs that replace Cyt targets for methylation in their specific recognition site Friedman, 1986; Santi et al., 1984) . Since the methylation target for the mammalian maintenance methyltransferase, Dnmt1, is CpG in hemi-methylated sites (Figure 2 ), significant inhibition of DNA synthesis due to lack of repair of Dnmt1-ZCyt adducts does not occur for at least two cell cycles (Davidson et al., 1992) . In contrast, Dnmt1 becomes bound to DNA and inactivated as soon as ZCyt is incorporated into CpG sites opposite a methylated CpG site on the template strand, i.e., within a few hours of initiating treatment with ZCyd or ZdCyd. This, in turn, leads to rapid passive loss of methylation ( Figure 2b ) (Creusot et al., 1982) . In this regard, it is of interest to note that the level of cellular resistance to the toxic effects of ZCyd and ZdCyd is inversely correlated with the level of active Dnmt1 rather than the level of ZCyt in DNA (Flatau et al., 1984; Juttermann et al., 1994) . The finding that cells selected for resistance to ZdCyd are still capable of incorporating ZdCyd into their DNA to the same extent as untreated cells, suggests that resistance to ZCyd toxicity occurs because the probability that Dnmt1 will encounter and become covalently bound to ZCyt in hemimethylated CpG sites is greatly reduced even when Dnmt1 levels have returned to normal (Flatau et al., 1984) .
Role of altered DNA methylation in cancer
Reduced methylation of DNA in cancer
The first hint that there was a link between methylation and cancer came from studies showing that 5-methylcytosine (MCyt) levels were lower in DNA of tumor cells as compared to normal cells (Gama-Sosa et al., 1983; Lapeyre and Becker, 1979; Lapeyre et al., 1981) . It was soon demonstrated that loss of DNA methylation was an early event in tumorigenesis, occurring even in preneoplastic colonic epithelium of individuals with familial polyposis coli (Feinberg et al., 1988; Feinberg and Vogelstein, 1987; Goelz et al., 1985) . Hypomethylation of H-ras and MYC genes is common in a variety of human tumors (Fang et al., 1996; Feinberg and Vogelstein, 1983; Sharrard et al., 1992; Vachtenheim et al., 1994) , but it has not been linked to overexpression of these genes in cancers. However, severe dietary deficiency of sources of methyl groups (lipotropes: choline, methionine, vitamin B12 and folate) was found to lead to development of hepatocellular carcinoma in rats and to enhance development of carcinogen induced tumors (Ghoshal and Farber, 1984; Lombardi and Shinozuka, 1979; Mikol et al., 1983; Newberne and Rogers, 1986) . Although Dnmt1 activity in hepatocytes was elevated 2 -3-fold, probably due to cell division induced by the methyl deficient diet, passive loss of DNA methylation occurred due to continued synthesis of DNA in hepatocytes under conditions of limiting 5-adenosylmethionine (AdoMet) and elevated 5-adenosylhomocysteine (AdoHcy). Decreased methylation in liver DNA could be detected within a few days of initiating the feeding of a methyl deficient diet (Christ- , 1993a,b; Dizik et al., 1991; Wainfan et al., 1989) . Even with limited site-specific methylation analysis, it could be demonstrated that decreases in methylation only occurred in a limited subset of CpG sites. Loss of methylation at these sites persisted for at least 9 months after the animals were returned to a normal diet, suggesting that little de novo methylation occurred once the mitogenic stimulus of methyl deficiency was no longer present. In this rat model for preneoplastic liver and in several human tumor types, a correlation could be observed between decreased methylation levels and increased expression of specific genes (reviewed in Christman, 1995; Ehrlich, 2000) . Paradoxically, studies with cultured cells indicated that inhibitors of DNA methylation, such as Lethionine and ZCyd, two compounds that inhibit DNA methylation by totally different mechanisms, could lead to activation of a differentiation program in a variety of human and murine cell lines derived from tumors and normal tissues (Christman et al., 1977; Constantinides et al., 1977; Creusot et al., 1982; Mendelsohn et al., 1980; Taylor and Jones, 1979; Taylor and Jones, 1982; reviewed in Zingg and Jones, 1997) . In part, this apparent discrepancy was reconciled by the demonstration that in CH310T1/2 cells, where treatment with ZCyd caused the cells to differentiate into muscle, chondrocytes and adipocytes (Constantinides et al., 1977) , it also caused reactivation of MyoD1, a gene that plays a vital role in myocyte differentiation. Although the function of MyoD1 is not regulated by methylation during normal development, the CpG island in the regulatory region of the gene presumably became de novo methylated during establishment of the cells in culture .
Increased methylation of DNA in cancer
CpG islands are stretches of DNA approximately 1 kb long that are rich in CpG and GpC dinucleotides (Bird, 1986) . The CpG sites in these gene-associated regions are rarely methylated in normal cells with the exception of CpG islands of genes on the inactivated X chromosome and CpG islands associated with imprinted genes (Barlow, 1995) . It is now accepted that abnormal methylation of CpG islands is not restricted to cultured cells but can also occur during aging and during tumor development Issa et al., 1996; Wilson and Jones, 1983) . The mechanism by which hypermethylation of selected CpG islands occurs in cells undergoing an overall decrease in level of cytosine methylation remains to be resolved. However, it has now been shown that unmethylated CpG islands associated with a variety of genes become partially or fully methylated in tumors and can be reactivated by ZCyd (Table 1) . Some of these genes appear to be 'bystanders' that are not expressed in either the normal tissue or the tumor arising from it but are methylated in the tumor (Silverman et al., 1989) . Similarly, some CpG island methylation has no effect on gene activity because it occurs in CpG islands that are not associated with the regulatory regions of genes (Jones, 1999; Nguyen et al., 2001) . Over the last 10 years, it has been well documented that loss of tumor suppressor gene function can occur both through mutation and through gene silencing linked to methylation of CpG island promoters (reviewed in Baylin et al., 1998; Santini et al., 2001) . A recent examination of more than 600 primary tumor samples from 15 tumor types showed that CpG island promoters of three or more genes from a panel of 12 known tumor suppressor genes were hypermethylated in 5 -10% of the samples. At least one CpG island was methylated in 80% or more of samples for each tumor type . Using methods that allow genome wide screening of CpG islands, it has been estimated that, on average, *1% of CpG islands in DNA from tumor tissues are abnormally methylated (Costello et al., 2000; Yan et al., 2001) . These studies also provide evidence for tumor specific patterns of CpG island methylation, with the percentage of CpG island methylation in individual tumors varying from 0 -10% of the *45 000 CpG islands in the human genome (Costello et al., 2000) . There is also evidence of silencing of the p53 tumor suppressor gene as a result of methylation of CpG sites in its 'non-CpG island' promoter and of hypermethylation of these sites in human hepatomas (Pogribny and James, 2002; Pogribny et al., 2000) .
There are a number of examples of treatment with ZCyd or ZdCyd leading to reactivation of function in tumor cell lines in which one copy of a gene for a tumor suppressor, a cell cycle regulator or a DNA repair enzyme is mutated and the other is normal (wild type) but inactivated by methylation. This suggests that loss of methylation induced by ZCyd or ZdCyd treatment can lead to reactivation of the same genes whose inactivation was selected for during development of a specific tumor and has stimulated interest in revisiting the use of ZdCyd and other Cyd analogs in anticancer therapy . This review will provide an overview of the mechanistic attributes of DNA (C5) MTases and discuss how these characteristics could explain why ZCyt in DNA affects both DNA methylation and acts to trigger apoptosis in cancer cells.
DNA cytosine (C5) methyltransferases: enzyme structure and catalytic mechanism
The catalytic mechanism of DNA (C5) MTases involves formation of a covalent bond between a cysteine (Cys) residue in the active site of the enzyme and carbon 6 (C6) of cytosine (Cyt) in DNA. This increases flow of electrons to carbon 5 (C5), with subsequent attack on the methyl group of AdoMet. Abstraction of a proton from C5 followed by belimination then allows reformation of the 5 -6 double bond and release of the enzyme and DNA with a methylated Cyt (Figure 3a) . Santi et al. (1984) proposed a mechanism that would account for the (Christman et al., 1985; Friedman, 1986; Gabbara and Bhagwat, 1995; Santi et al., 1984) .
It is assumed that the mammalian DNA (C5) MTases accomplish methyl transfer and are inhibited by ZCyt in the same manner as the bacterial DNA (C5) MTase, M.HhaI, since these enzymes share a set of conserved catalytic domain motifs (Lauster et al., 1989; Posfai et al., 1989) . These include a prolylcystineyl active site dipeptide (region IV), a group of separate domains that come together to form the binding pocket for AdoMet (I, X) and a region (VI) containing the glutamyl residue that protonates nitrogen 3 (N3) of the target Cyt. The recognition domain that makes basespecific contacts in the major groove of DNA usually lies between motifs VIII and IX.
X-ray crystallographic analysis of a ternary complex containing AdoHcy and M.HhaI with the cysteine (Cys81) of the prolylcysteinyl dipeptide covalently linked to FCyt in DNA (F13) demonstrated that the covalently linked target Cyt is flipped out of the DNA helix into the catalytic pocket of the MTase. The structure predicts that C5 of a flipped target Cyt is aligned with a bound AdoMet molecule and C6 with the thiolate residue of the active site cysteine (Cys81) in a manner that facilitates a concerted attack and methyl transfer (Klimasauskas et al., 1994) . As determined in modeling studies (O'Gara et al., 1996a) , once methyl transfer from AdoMet to C5 occurs, a tension develops between the methyl group on C5 of the flipped MCyt and adjacent amino acids Pro80 and Cys81, destabilizing the enzyme DNA complex sufficiently to allow release of the methylated product.
There is as yet no high resolution X-ray crystal structure of M.HhaI complexed with a ZCyt target in DNA. However, the enzyme has been crystallized in a ternary complex with AdoHcy and a synthetic oligodeoxyribonucleotide (ODN) containing a 5,6-dihydroazacytosine (DZCyt) residue as target in a hemimethylated site (DZ13 - Figure 4a ; Sheikhnejad et al., 1999) . The only difference between DZCyt and ZCyt is the degree of saturation of the bond between C5 and C6 (Figure 1b,c) . The completely saturated C5-C6 bond in DZCyt makes it an analog of the covalently bound transition state of Cyt and ZCyt formed prior to methyl transfer, while the sp 3 character of C6 abrogates nucleophilic attack. The structure of the protein and DNA components in the DZ13 complex closely approximate those of HM13, a complex of AdoHcy, M.HhaI with an identical ODN containing a Cyt residue as target in a hemimethylated site. While no methylation of Cyt can occur in either complex, there is a major difference between HM13 and DZ13 -the distance between C6 and the sulfur atom of Cys81. In DZ13 this distance is 3.1 Å ( Figure  4a ) compared to 2.6 Å in HM13 and 1.8 Å for the covalently linked C5 and Cys81 in F13 (Figure 4b ). It has been noted that, even in the absence of methyl transfer in HM13, both C5 and C6 of the Cyt target take on some sp 3 character and that the reduced distance between C6 and Cys81 suggest a 'partial' covalent bond formation (O'Gara et al., 1996b) while the separation of these atoms in DZC indicates a complete lack of reaction between C6 and Cys81 in DZCyt (Sheikhnejad et al., 1999) . The distance between Glu 119 and N3 in DZ13 is 3.3 Å compared to 2.8 Å in F13 suggesting a lack of protonation of N3 in DZ13. Other contacts between the protein and base in DZ13 are similar to those of Cyt in HM13 although there is a weaker interaction between N4 of DZCyt and Glu 119. The presence of an additional hydrogen bond between the proton on N5 and water may help to stabilize DZCyt complexes. Thus, with the exception of Cys81, the relationship of DZCyt to specific aminoacid residues in M.HhaI in complex DZ13 should closely approximate that of an intact ZCyt target after formation of a covalent linkage.
A model for the proposed mechanism of action of M.HhaI is shown in Figure 5 . The enzyme associates with DNA in a sequence independent manner and scans or diffuses until it encounters its recognition site (Figure 5a ). Interaction with non-specific DNA can orient the cofactor, AdoMet so that its methyl group is optimally positioned with respect to the target Cyt-C5 (O'Gara et al., 1999). On encountering its specific binding/recognition site, the enzyme forms an 'open' complex comprised of 'an ensemble of flipped out conformers' (Figure 5b 1,2 ) and finally a more compact or 'closed' complex ( Figure 5c ) in which Ser87 in the flexible loop of the enzyme comes together with Gln 287 in the recognition domain and locks the 'flipped' target Cyt into the catalytic pocket (Klimasauskas et Figure 4 Comparison of the interaction of DZCyt (a) and Cyt (b) with M.HhaI. Difference electron density maps (F 0 -F c' a c ) superimposed on the refined coordinates with carbon atoms colored black, oxygen atoms red, nitrogen atoms blue, and sulfur atoms green, respectively. Reproduced with permission from Sheikhnejad et al. (1999) and Klimasauskas et al. (1994) . These publications contain additional detail (Klimasauskas and Roberts, 1995) . Normally, when AdoMet is present, ternary complexes with M.HhaI and DNA with a Cyt target are not detected due to release of the enzyme after methylation of the Cyt residue. However, highly stable ternary complexes between M.HhaI and Cyt targets (t1 2 of dissociation 49 h) can be formed when the enzyme lacks an active site Cys81 (Mi and Roberts, 1993) , providing evidence that methylation is necessary to destabilize the closed complex with Cyt (Figure 5d ). Analysis of the crystal structure of the ternary complex between M.HhaI and a 5MCyt target (M13) (O'Gara et al., 1996a) , suggest that the steric tension between the C5-methyl group and Pro80 could play a role in opening of the complex and release of the methylated product (Figure 5e ).
Although it is still not understood how the flipping of the base is initiated, it is clear that M.HhaI does not 'recognize' the base that is to be flipped, but rather the sugar phosphate backbone and the sequences flanking the target. M.HhaI forms 'closed' ternary complexes with AdoHcy and DNAs containing a variety of purine and pyrimidine bases substituted for the Cyt target in the GCGC recognition site of the enzyme (Klimasauskas and Roberts, 1995; O'Gara et al., 1999; Yang et al., 1995) . Even in the absence of a base, the sugarphosphate backbone of DNA can assume a 'flippedout' conformation in ternary complex with M.HhaI (Cheng and Roberts, 2001 ). However, the stability of the 'closed' complexes with bases other than Cyt varies greatly and, with few exceptions, formation of 'closed' complexes requires the presence of AdoHcy (Klimasauskas and Roberts, 1995; Sheikhnejad et al., 1999; Yang et al., 1995) . The rank order of binding strengths and rates of dissociation, in conjunction with the data from X-ray crystallographic analysis of a large array of M.HhaI ternary complexes (Cheng and Roberts, 2001) , suggest that suboptimal interactions between noncytosine bases and the amino acid contacts in the active site play a critical role in reducing complex stability, favoring reopening of the complex and release of the flipped base (Sheikhnejad et al., 1999) .
Structural determinants of the stability of 'closed' complexes with ZCYT-ODNs
There are at least three exceptions to the rule that cofactor is necessary for formation of 'closed' complexes between M.HhaI and potential substrates. Electrophoretic mobility on native gels demonstrated that M.HhaI complexes with ODNs containing DZCyt as a replacement for the Cyt target of M.HhaI had the same 'closed' mobility in the presence of AdoMet or AdoHcy or in the absence of cofactor (Sheikhnejad et al., 1999) . Identical behavior was noted for ODNs with abasic carbocyclic and furanose sugars in place of Cyt (Wang et al., 2000) . An improved method for the automated synthesis of ODNs containing ZCyt (Garcı´a et al., 2001 ) allowed us to examine the formation of complexes between M.HhaI and ZCyt-ODN and to determine that formation of 'closed' complexes with ZCyt-ODN is also independent of cofactor (Brank et al., in preparation) . However, unlike complexes with DZCyt and AP-ODNs, which have monophasic However, in the second phase, the t1 2 for complex dissociation ranged from 44 days in the absence of cofactor to 42 -3 weeks for complexes formed in the presence of AdoMet or AdoHcy.
As diagrammed in Figure 6 , there are a variety of breakdown products of ZCyt that can form in aqueous solution or after covalent linkage of ZCyt to DNA MTase. Analysis by mass spectrometry of ODNs used in our studies indicated that the purified ODNs contained only two forms of ZCyt, the intact base (I) and a small amount of the ring-open form that has undergone loss of C6 as formate (IVa) (Garcı´a et al., 2001) . Thus, it is most probable that the first phase of dissociation represents rapid dissociation of enzyme from ODNs containing IVa and the second phase, an extremely slow dissociation of ZCyt-ODN covalently linked to enzyme (IIb). Complexes formed between M.HhaI and ODNs containing the ring-open form IVa (ZCyt-IVa-ODN) would be expected to be much less stable than those resulting from covalent binding to intact ZCyt (IIb). While several of the structural features of the Cyt ring interaction with amino acids in the catalytic pocket of M.HhaI could be maintained in ZCyt-IVa-ODN, i.e. the N3,N4 interactions with Glu119, the O2 and phosphodiester backbone interactions with Arg165 and the N3 amino group interaction with Pro80 (O'Gara et al., 1996a), ZCyt-IVa ODN has lost any possibility of stabilization through formation of a partial or complete covalent bond between C6 of ZCyt and Cys81 of M.HhaI. In addition, formation of an alternate ring structure through intramolecular hydrogen bond formation (Structure V; JacksonGrusby et al., 1997) could interfere with enzyme/ DNA interactions such as the one between O2 and Arg165. The predicted poor fit of V in the catalytic pocket would suggest that it should be similar to a mismatched base in its stability under non-denaturing conditions. The t1 2 for the rapid phase of dissociation of ZCyt complexes and magnitude of the enhancement of binding by AdoHcy (*50%) is similar to that of ODNs with Ade and Ura replacing Cyt (Sheikhnejad et al., 1999, and unpublished AS Brank, JK Christman) . In this regard, it may be significant that a small proportion of binary complexes with ZCyt-ODN migrate in native gels with the slower rate characteristic of 'open' complexes, while only 'closed' complexes are seen in the presence of cofactor (Brank et al., in preparation) .
The observation that M.HhaI : ZCyt-ODN complexes with an extremely slow rate of dissociation form in the absence of cofactor or the present of AdoHcy is consistent with Santi's proposal (Santi et al., 1984 ) that addition of a proton at N5 leads to formation of a stable but slowly reversible covalent bond between DNA (C5) MTases and ZCyt in DNA and that methylation of ZCyt residues is not necessary for covalent bond formation. In agreement with this, transfer of radiolabeled methyl groups from AdoMet to ZCyt-ODNs by M.HhaI was barely detectable (AS Brank and JK Christman, unpublished data) . A standard test of covalent linkage between FCyt residues in DNA and MTasesis to heat the complexes to 958C in the presence of these denaturants. None of the DZCyt-, ZCyt-and AP-ODNs complexes formed with M.HhaI in the presence or absence of cofactor survive this treatment (Brank et al., in preparation; Sheikhnejad et al., 1999) . This was expected because no covalent bonds can be formed with DZCyt-or furanoses, and ring opening of ZCyd is promoted by heating (Beisler, 1978) . However, ODNs containing any of these three targets form 'closed' complexes that are stable in the presence of SDS and 2-mercaptoethanol at 228C regardless of the presence or absence of Figure 6 Reaction pathways for ring opening and hydrolysis of 5-azacytosine residues in DNA in solution (a) and after covalent linkage to the active site cysteine of a DNA (C5) MTase (b). Note that the end result of these pathways is the same, an unliganded DNA with a potentially mutagenic base residue (V). However, the interaction in path (b) leads to inactivation of the enzyme through formylation of the catalytic cysteine If it is assumed that ZCyt in both binary and ternary complexes of ZCyt-ODN with M.HhaI is covalently linked to the enzyme and has the same basic structure as DZCyt in DZ13, the major difference between ZCytand FCyt-ODNs in the complexes is evident. Formation of stable complexes between M.HhaI and FCytODNs requires transfer of a methyl group to the FCyt target while methylation of the ZCyt target in ZCytODNs is not only unnecessary but is actually a rare event. Thus, at 228C, under denaturing conditions, the covalent complex between enzyme and methylated FCyt-ODN takes on a variety of conformations ranging from tightly closed to fully 'open' because the presence of the (C5)-methyl group destabilizes the complex. With increased temperature, the equilibrium is shifted to the fully 'open' form (Figure 7 and unpublished data, AS Brank and JK Christman). All of the M.HhaI : ZCyt-ODN complexes, regardless of the presence or absence of co-factor, migrate with the same increased mobility that we postulate is the result of the 'closed' configuration assumed by M.HhaI when the active site loop (residues 80 -90) locks the flipped-out target into catalytic pocket. M.HhaI : DZCyt-ODN complexes have an identical mobility to M.HhaI : ZCyt-ODN complexes in the presence of SDS and 2-mercaptoethanol at 228C (DZCyt), but are less stable to heating. This provides support for the proposal that ZCyt in the high mobility M.HhaI : ZCyt-ODN complex has the same non-aromatic ring structure with saturation of the 5,6 double bond between C6 and the N5 (Structure IIb) and suggests that the added stability and slower dissociation rate of the M.HhaI : ZCyt-ODN complex (t1 2 4100 h) relative to the M.HhaI : DZCyt-ODN complex (t1 2 54 h in the presence of AdoMet) is due to the covalent bond. The slow but measurable dissociation of ZCyt-ODN from M.HhaI : ZCyt-ODN complexes observed in our studies could be related to the rate at which covalently linked ZCytIIb is converted to either form I or form It is important to note that Dnmt1 : FCyt-and ZCyt-ODN complexes exhibit similar properties to M.HhaI : FCyt-and M.HhaI : ZCyt-ODNs with regard to stability and altered mobility during electrophoresis on denaturing gels (Figure 8 ). This means that inferences drawn from our studies of interactions between M.HhaI and ZCyt in DNA are relevant to the understanding of the effects of ZdCyd or DZCyd incorporation into DNA during cancer therapy.
Implications of the interactions between DNA (C5) MTases and Cyt analogs in DNA for cancer therapy
Although there are a variety of compounds that can inhibit DNA methylation in mammalian cells (Zingg and Jones, 1997) , the only DNA MTase inhibitors that have undergone extensive clinical trial are ZCyd, DZCyd (5, DHAC) and ZdCyd (Decitabine). All three compounds are inhibitors of DNA methylation only when incorporated into DNA. As noted, ZdCyt is more potent an inhibitor of DNA methylation than ZCyt because it is only incorporated into DNA. DZCyd, which was synthesized as a more stable analog of ZCyd (Beisler, 1978) is at least an order of magnitude less potent than ZCyt in blocking in vivo methylation (Jones and Taylor, 1980; McGregor et al., 1989) . This has been ascribed to limited incorporation DZCyt into DNA because it is inefficiently phosphorylated by cytidine kinase (McGregor et al., 1989) .
ZCyt Santini et al., 2001) . The number of clinical trials of anti-tumor effects of ZCyd, ZdCyd and DHAC on solid tumors is relatively small and reported responses are generally low and/or lower than conventional therapy. Nevertheless, a recent pilot Phase I/II trial of ZdCyd for metastatic lung cancer indicated 'some clinical activity' (Momparler et al., 1997) .
Fifteen years ago, Glover et al. (1987) summarized a review of ZCyd trials with the comment 'Azacitidine has been undergoing clinical trials for almost 20 years and is internationally considered to have a useful place in the treatment of acute nonlymphocytic leukemia. However, its role in the various combinations for induction, intensification, maintenance, or relapse regimens has not yet been clearly defined'. It is still difficult to make the determination as to whether ZCyd or Decitabine act primarily through cytotoxicity or through effects on DNA methylation (Daskalakis et al., 1999) . With high levels of incorporation of ZCyt into DNA, it is likely that cytotoxicity predominates due to formation of Dnmt : ZCyt adducts in DNA. Clonal outgrowth of cells resistant to ZCyd or Decitabine toxicity, either because they are not synthesizing DNA during the period of treatment or because they have few methylated CpG targets, could easily account, not only for observed switches to a 'normalized' karyotype, but also for differences in methylation patterns pre-and post-treatment. It is of interest in this regard that a recent report suggests that Dnmt1 : ZCyt adducts in DNA can activate the p53 DNA damage response pathway in cells with wild-type p53 and that p53/p21 Figure 8 Comparison of the SDS -PAGE mobility of complexes between purified rDnmt1 (Brank et al., 2002) and FCyt-(lanes 1 -3), ZCyt-(lanes 4 -6) or Cyt-ODN (lane 7). Details as in Figure  7 . Samples were electrophoresed on 6% SDS-polyacrylamide gels without heating. The increase in mobility with binding of ZCyt ODN is indicated (*). Note the broad smear of conformers is detected for covalently linked methylated FCyt-ODN and that only free ODN was detected in lane 7 5-Azacytidine and DNA methylation JK Christman activation could contribute to clinical efficacy of ZCyt and ZdCyd in cancers such as CML where functional p53 is often retained (Karpf et al., 2001) .
Our studies with ODNs containing ZCyt and DZCyt suggest that these inhibitors will have different effects on DNA repair and mutation. In mammalian cells, covalent ZCyt complexes are toxic (Juttermann et al., 1994) and after resolution by hydrolysis leave a base remnant that is mutagenic (Jackson-Grusby et al., 1997) . DZCyt is stable in DNA but cannot form covalent complexes with DNA MTases. Further although it forms 'closed' complexes with M.HhaI, AdoMet has a much weaker capacity for stabilizing these complexes than does AdoHcy (Sheikhnejad et al., 1999) . Under physiological conditions, AdoMet is generally well in excess of AdoHcy (Shivapurkar and Poirier, 1983) . Thus, reversibility of Dnmt1 : DZCyt-DNA complex formation and the low efficiency of incorporation of DZCyd into DNA may be equal contributors to the low potency of DZCyd as an in vivo inhibitor of methylation. However, the reversibility of DZCyt complex formation should also allow normal DNA replication with incorporation of G opposite the analog, suggesting that treatment with DZCyt will have a much lower potential for inducing mutations than treatment with ZCyt.
Perspectives and future directions
Considering that both ZCyd and ZdCyd have the common side effect of inducing nausea, vomiting, diarrhea and myelosuppression that limit doses and duration of treatment and that both have the potential to form mutagenic lesions, it is clear that better inhibitors of DNA methylation are needed for clinical use. While DZCyd has the advantage of lower toxicity and mutagenic potential, it has not proven to be particularly effective at inducing a therapeutic response. With a better understanding of how mechanism based inhibitors interact with DNA methyltransferases, it should be possible to design small 'decoy' DNAs containing these inhibitors for use as therapeutics (Brank et al., in preparation; Garcı´a et al., 2001; Sheikhnejad et al., 1999; Wang et al., 2000) . Dnmt1, the most abundant of the three catalytically active DNA MTase in mammalian cells (Figure 9 ) and the best studied, is assumed to be the major target for inhibition by Cyt analogs in DNA. As summarized in Figure 9 and reviewed in Robertson (2001) Dnmt1 interacts with a number of proteins that link the enzyme to the nuclear matrix, target it to replication foci and repair sites. In addition, there are sites for binding of histone deacetylases and other proteins involved in transcriptional repression. The finding that ZCyt can induce the same kind of major conformational change in Dnmt1 as it does in M.HhaI suggests an alternate mechanism for the effect of ZCyt and DZCyt in DNA on gene expression, i.e., altering Dnmt's interaction with other proteins. For example, it will be important to determine whether the 'closed' conformation induced in Dnmt1 and other DNA MTases when bound 'decoy' ODNs containing ZCyt and DZCyt in CpG sites weakens interactions between Dnmt1 and transcriptional repressors. In the cell, this could result in both inhibition of methylation and dissociation of HDAC's, leading to rapid remodeling of chromatin and resumption of gene expression. Similarly, weakened interactions with proteins at the replication foci or in the nuclear matrix could profoundly affect maintenance of methylation required for continued compaction of inactive chromatin and nuclear localization of Dnmt1.
Nothing is known about the effect of ZCyt and DZCyt in DNA on the activity or conformation of Dnmt3a and 3b. These recently identified de novo methyltransferases would be predicted to have the same response to these inhibitors as M.HhaI and Dnmt1 but this remains to be proven. Theoretically, Dnmt3a and 3b could be much more sensitive to the inhibitory effects of ZCyt and DZCyt incorporated into DNA since they are randomly incorporated in place of Cyt and, unlike Dnmt1, Dnmt3a and 3b are capable of methylating Cyt residues that are not in CpG sites (Aoki et al., 2001; Gowher and Jeltsch, 2001 ). However, this difference in site specificity should be an advantage in development of specific inhibitors of de novo methylation that could potentially prevent remethylation of genes activated by use of Dnmt1 inhibitors. The better our understanding of the similarities and difference in the mechanisms by which Figure 9 Structure of the catalytically active mammalian DNA methyltransferases. All three enzymes have a regulatory and catalytic domain. The conserved motifs of the catalytic domain (Roman numerals) are discussed in the text. Other structural features of Dnmt1 are the domains for nuclear localization, targeting to replication foci, and zinc binding. Binding regions for proteins involved in linkage to the nuclear matrix (p23 (Zhang and Verdine, 1996) , annexin V (Oshawa et al., 1996) ) or transcriptional repression (HDAC1 (Fuks et al., 2000) , HDAC2-DMAP1 (Rountree et al., 2000) , pRb/DMAP1, (Robertson and Wolffe, 2000) ) and targeting to replication and repair sites (PCNA (Chuang et al., 1997) ) are indicated. Dnmt3A and 3B share a cysteine rich PHD (plant homeodomain) region (Aasland et al., 1995) and regulatory regions binding with transcriptional repressors interacting with HDAC1 Fuks et al., 2001) inhibitors of DNA methylation affect the catalytic function of Dnmt1, 3a and 3b and protein interactions of these Dnmt's and the inactive Dnmt-like proteins, the greater the likelihood of developing novel anticancer drugs that can reactivate genes silenced in tumor cells.
